A study of effectiveness of injection Depot medroxyprogesterone in postpartum women

Priya G. Dhameliya; Parul T. Shah; Shlok V. Patel; Dhanvi J. Deliwala; Kinjal Kotahri

doi:10.18203/2320-1770.ijrcog20212967

Authors

Priya G. Dhameliya Department of Obstetrics and Gynaecology, NHL, MMC, Ahmedabad, Gujarat, India
Parul T. Shah Department of Obstetrics and Gynaecology, NHL, MMC, Ahmedabad, Gujarat, India
Shlok V. Patel Department of Obstetrics and Gynaecology, NHL, MMC, Ahmedabad, Gujarat, India
Dhanvi J. Deliwala Department of Obstetrics and Gynaecology, NHL, MMC, Ahmedabad, Gujarat, India
Kinjal Kotahri Department of Obstetrics and Gynaecology, NHL, MMC, Ahmedabad, Gujarat, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20212967

Keywords:

Injection DMPA, Postpartum contraception, Fertility

Abstract

Background: Depot medroxyprogesterone (DMPA) injection 150 mg intramuscular was used in postpartum women for contraception in this study, once every 3 months. The aim of the study acceptance and compliance of DMPA, observe side effects related to usage of DMPA and establish its effectiveness as a postpartum contraception method.

Methods: This is a prospective study carried out at Obstetrics and Gynaecology department over a period of 9 months and follow up was done. Only patients of full term normal delivery and Lower segment caesarean section (LSCS) were included. They were counselled properly and after their willingness for enrolment they were included in study after taken consent.

Results: Out of 50 cases selected maximum patients, 48% were in the age group of 26 to 30, 38% were from lower socioeconomic class. Amenorrhoea and irregular spotting were found in 68% and 42%respectively. There was no case of failure of this contraceptive method in this study.

Conclusions: DMPA is an effective and safe method of contraception in lactating period. Proper counselling will increase acceptance of DMPA. Awareness in patients regarding its benefits as compared to other contraceptive methods.

Metrics

Metrics Loading ...

References

WHO- family planning/contraception method. https://www.who.int/news-room/fact-sheets/deta il/family-planning-contraception. Accessed on 10th May, 2021.

Isabel M, Rodriguez MI. An evidence-based approach to postpartum use of depot medroxyprogesterone acetate in breastfeeding women, controversies in reproductive health. 2009;80(1):4-6.

Singhal S, Sarda N, Goel S. Impact of injectable progestogen contraception in early puerperium in lactation and infant health. JDCR.

Depot medroxyprogesterone acetane(DMPA). The oncofertility consortium. https://oncofertility.m su.edu/resources/depot-medroxyprogesterone-acetane-dmpa. Accessed on 10th May, 2021.

Fotherby K. J Obstet Gynaecol (Lahore). 1986;2:S110-5.

Kaunitz, Andrew M. Injectable long-acting contraceptives. Clin Obst Gyncol. 2001;44(1):73-91.

Hanson SJ, Burke, Anne E. Fertility control: contraception, sterilization, and abortion. In: The Johns Hopkins Manual of Gynecology and Obstetrics. Kurt H. 4th ed. Wolters Kluwer Health, Philadelphia, USA: Lippincott Williams & Wilkins. 2010;382-95.

Funded by the Susan Thompson. N Engl J Med. 2012;366:1998-2007.

Andrew M, Kaunitz. Return to fertility, Clinical obstetrics and gynecology. 2001;44(1):73-5.

Contraception/injectable progestin contraceptives. In: Williams Obstetrics. Chapter 38 2th edition.